Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553666 · ClinicalTrials.gov registry record · Phase 2
Reducing Frailty for Older Cancer Survivors Using Supplements
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04553666: Completed Phase 2 study, sponsored by University of Rochester.
NCT04553666 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04553666, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
Primary Outcome
Recruitment feasibility will be determined by the proportion of participants approached compared to those consented onto the study.
Interventions
- DRUG Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
What the finished NCT04553666 record still lists
NCT04553666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) is the first listed.
NCT04553666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04553666 about?
NCT04553666 is a clinical study titled "Reducing Frailty for Older Cancer Survivors Using Supplements". The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
What is the current status of trial NCT04553666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-04-28. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04553666?
The interventions under investigation include: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) (DRUG).
Who is sponsoring clinical trial NCT04553666?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04553666's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI